Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing…
Month: December 2019
Disclaimer
Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing…
Are you sure you want to leave ObsEva.com?
We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.
Linzagolix Phase 3 PRIMROSE 2 Trial Results
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT…
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
Geneva, Switzerland and Boston, MA –December 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…